Biohaven Pharmaceutical Holding Co (NYSE: BHVN) — Company Overview, News & Financial Data
Biohaven Pharmaceutical is dedicated to developing therapies for neurological disorders, focusing on innovative clinical trials.
Biohaven Pharmaceutical Holding Co
Biohaven Pharmaceutical (NYSE:BHVN) focuses on developing innovative therapies for debilitating neurological and neuropsychiatric diseases, including rare disorders. The company's research and development efforts are primarily concentrated on advancing a pipeline of novel compounds targeting key pathways involved in a range of central nervous system disorders. With several projects in clinical trials, Biohaven is committed to bringing new treatments to market that address unmet medical needs. Its objective is to improve the lives of patients suffering from serious conditions by harnessing the power of cutting-edge science. As of my last update, Biohaven Pharmaceutical is solely listed on the New York Stock Exchange under the ticker symbol (NYSE:BHVN), with a strong dedication to excellence in all aspects of its operations from research to patient care.
Snapshot
Operations
Products and/or services of Biohaven Pharmaceutical Holding Co
- Rimegepant, a CGRP receptor antagonist for migraine treatment, offers rapid relief and can be used for both preventative and acute therapy.
- Zavegepant nasal spray, targeting CGRP receptor for acute migraine treatment, provides an alternative delivery system for patients.
- Troriluzole, a drug for neurodegenerative diseases like Alzheimer's and obsessive-compulsive disorder, aims at modulating glutamate to protect neurological function.
- Verdiperstat, an oral myeloperoxidase inhibitor, focuses on treating multiple system atrophy, aiming to slow disease progression through anti-inflammatory effects.
- BHV-5000, targeting NMDA receptor modulation, is investigated for potential in neuropsychiatric disorders and epilepsy, aiming at a new therapeutic approach.
Biohaven Pharmaceutical Holding Co executive team
- Vladimir CoricChairman & CEO
- Matthew ButenChief Financial Officer
- Kimberly GentileSenior Vice President of Clinical Operations
- Bruce D. CarChief Innovation Officer
- Deb YoungSenior Director of Regulatory Affairs & Operations
- George C. ClarkVP & Chief Accounting Officer
- John McGillChief Technology Officer
- Jennifer PorcelliVice President of Investor Relations
- Warren VollesGeneral Counsel & Chief Legal Officer
- Clifford BechtoldPresident & GM of Biohaven Ireland Chief Compliance Officer
Latest news about Biohaven Pharmaceutical Holding Co
Biohaven signs Ono deal worth up to $100 million
United StatesBiohaven to present BHV-1530 cancer data
United StatesBiohaven signs $795 million global licensing agreement
United StatesBiohaven and Yale secure $4 million verdict in trade secret and contract dispute
United StatesBiohaven autoimmune degraders clear key biomaker milestones as Phase 3 nears
United StatesBiohaven seizure drug extends remission in broad clinical data update
United States
Key financials
Reported results for Biohaven Pharmaceutical Holding Co, in USD.
- Market cap
- 2.3B
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -4.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -745.4M | -738.8M | |
| 0 | -885.1M | -846.4M | |
| 0 | -436.1M | -408.2M | |
| 0 | -567.9M | -570.3M |